Learning Objectives
1. Classify patients, assess control, and select and monitor appropriate acute and preventive treatments for pediatric and adult patients with asthma and for adult patients with chronic obstructive pulmonary disease, depending on patient-specific factors. 2. Assess, classify, and select appropriate acute and chronic pharmacotherapy (including nonpharmacologic therapy), and monitor, reassess, and adjust therapy in patients with gout. 3. Determine appropriate immunizations for an adult given his or her age and medical conditions and apply cautions, contraindications, and drug interactions with immunizations to adult patients.
Self-Assessment Questions
Answers and explanations to these questions can be found at the end of this chapter.
1.
A 20-year-old woman is admitted to the hospital for an asthma exacerbation. She states that she has been using her boyfriend's albuterol inhaler on a regular basis for the past 2 years. During the past few months, she has been using the inhaler throughout the day on a daily basis and sometimes at night. Which best classifies her asthma severity?
A. Mild intermittent.
B. Mild persistent.
C. Moderate persistent.
D. Severe persistent.
2. Which is the best maintenance therapy for her asthma?
A. Fluticasone low dose.
B. Montelukast.
C. Fluticasone medium dose plus salmeterol.
D. Theophylline.
3. Which type of measurement best classifies the number of times a short-acting β 2 -agonist (SABA) is used in 1 month?
A. Nominal.
B. Ordinal.
C. Interval.
D. Ratio. 4 . You are designing a study in which you will compare the percentage of patients with an asthmarelated hospitalization receiving fluticasone/ salmeterol with those receiving fluticasone alone. Which statistical test is best for analyzing this comparison?
A. Analysis of variance (ANOVA).
B. Chi-square.
C. Mann-Whitney U test.
D. Student unpaired t test.
5.
A 22-year-old woman with asthma is taking an albuterol metered dose inhaler (MDI) 2 puffs as needed and fluticasone (Flovent) 110 mcg/puff MDI 2 puffs twice daily. She received the influenza vaccine during last year's influenza season, and her last tetanus vaccine (tetanus, diphtheria, and pertussis [Tdap] ) was at age 17; there is no documentation of her having received a pneumococcal vaccine. Which is the best vaccine for her to receive at her next family medicine clinic appointment scheduled in July?
A. Influenza.
B. Pneumococcal.
C. Td (tetanus and diphtheria).
D. Herpes zoster.
6. A 60-year-old man with chronic obstructive pulmonary disease (COPD) has been using albuterol HFA 2 puffs four times per day as needed. His symptoms have worsened during the past year, and now he has persistent symptoms and shortness of breath, even while walking around his one-level house. ) requires uratelowering therapy (ULT). Which is the most appropriate drug and starting dose?
A. Probenecid 500 mg twice daily. A. Definition: Asthma is a chronic inflammatory disorder of the airways causing recurrent episodes of wheezing, breathlessness, cough, and chest tightness, particularly at night or early in the morning. During episodes, there is variable airway obstruction, often reversible spontaneously or with treatment. There is also increased bronchial hyperresponsiveness to a variety of stimuli. a. Cough is usually nonproductive with asthma and productive with COPD. b. FEV 1 is reversible with asthma but is irreversible with COPD. c. Cough is worse at night and early in the morning with asthma; occurs throughout the day with COPD. d. Asthma is often related to allergies and environmental triggers; patients with COPD have a common history of smoking or exposure to other irritants. e. Asthma can be reversible; lung damage from COPD is irreversible. 4. Asthma-COPD overlap syndrome (ACOS) a. Persistent airflow limitation with features of both asthma and COPD. b. If three or more features favor asthma, use diagnosis/treatment for asthma. c. If three or more features favor COPD, use diagnosis/treatment for COPD. d. If a similar number of features exist for both asthma and COPD, consider a diagnosis of ACOS (Table 1 ). 5. Exercise-induced bronchospasm a. Presents with cough, shortness of breath, chest pain or tightness, wheezing, or endurance problems during exercise. b. Diagnosis is made by an exercise challenge in which a 15% decrease in FEV 1 or peak expiratory flow occurs before and after exercise, measured at 5-minute intervals for 20-30 minutes. 
Table 2. Interpreting Spirometry

Component What It Measures
Normal Values FEV 1 Volume of air exhaled forcefully in the first second of maximal expiration
Normal is ≥80%
In asthma, reversibility is shown by an increase in FEV 1 of ≥12% after SABA FVC
The maximum volume of air that can be exhaled after full inspiration
Reported in liters and percentage predicted
Normal adults can empty 80% of air in <6 seconds FEV 1 
/FVC ratio
Differentiates between obstructive and restrictive disease Normal: Within 5% of predicted range, which varies with age; usually 75%-80% in adults Decreased in obstructive disease (asthma, COPD) (<70%) Normal or high in restrictive disease (pulmonary fibrosis) COPD = chronic obstructive pulmonary disease; FEV 1 /FVC = forced expiratory volume in 1 second/forced vital capacity; SABA = short-acting β-agonist. Table 5 )
C. Classification of Asthma Severity and Control
≥12
Step 1
Step 2
Step 3 d and consider short course of oral steroids
Step 4 or 5 and consider short course of oral steroids [5] [6] [7] [8] [9] [10] [11] Step 3 d or 4 and consider short course of oral steroids 0-4
Step 3 and consider short course of oral steroids a The patient is classified according to the sign or symptom that is in the most severe category. b Normal FEV 1 /FVC: 8-19 years old, 85%; 20-39 years old, 80%; 40-59 years old, 75%; 60-80 years old, 70%.
c Episodes lasting >1 day and risk factors for persistent asthma.
d For ages 5-11, initial step 3 therapy should be medium-dose ICS.
FEV 1 = forced expiratory volume in 1 second; FVC = forced vital capacity; ICS = inhaled corticosteroid; N/A = not applicable; SABA = short-acting β-agonist.
Adapted from NIH Asthma Guidelines. National Institutes of Health National Heart, Lung 
Patient Case
5.
A 25-year-old man presents to the ED with shortness of breath at rest. He is having trouble with conversation.
He used 4 puffs of albuterol MDI at home with no resolution of symptoms. His FEV 1 is checked, and it is 38% of predicted. Which is the best initial therapy for him in the ED, in addition to oxygen?
A. Oxygen alone is sufficient.
B. Give inhaled albuterol MDI 8 puffs every 20 minutes for 1 hour.
C. Give inhaled albuterol plus ipratropium by nebulizer every 20 minutes for 1 hour plus intravenous corticosteroids.
D. Give inhaled albuterol plus ipratropium by nebulizer every 20 minutes for 1 hour plus an OCS. , and the data for montelukast are reassuring. Considered an alternative therapy. e. Prednisone is category C; potential adverse effects in pregnancy are cleft palate, preeclampsia, gestational diabetes, low birth weight, and prematurity. However, few studies were of patients with asthma, and women might have been exposed to longer-term prednisone use. Prednisone should be used, if necessary, for acute exacerbations in pregnancy.
II. CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Guidelines:
Global A. Definition: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema and chronic bronchitis. Airflow obstruction may be accompanied by airway hyperresponsiveness and may be not be fully reversible. 1. Chronic bronchitis consists of persistent cough plus sputum production for most days of 3 months in at least 2 consecutive years. 2. Emphysema is abnormal permanent enlargement of the airspaces distal to the terminal bronchioles, accompanied by destruction of their walls and without obvious fibrosis.
B. Diagnosis and Assessment 1. The diagnosis of COPD is based on a history of exposure to risk factors and the presence of airflow limitation that is not fully reversible, with or without the presence of symptoms. a. Symptoms: Dyspnea (described by patients as "increased effort to breathe," "heaviness," "air hunger," or "gasping"), poor exercise tolerance, chronic cough, sputum production, wheezing b. GOLD guidelines: Perform spirometry and consider COPD if a patient is older than 40 years and has any of the following: i. Dyspnea that is progressive (worsens over time), persistent (present every day), and worse with exercise or on exertion ii. Chronic cough that is present intermittently or every day; often present throughout the day; seldom only nocturnal. May be nonproductive iii. Chronic sputum production in any pattern iv. History of exposure to risk factors, especially tobacco smoke (most common risk factor), occupational dusts and chemicals, and smoke from home cooking and heating fuels c. 2. Existing medications for COPD have not been shown to modify the long-term decline in lung function, the hallmark of this disease (level of evidence A). Therefore, pharmacotherapy for COPD is used to decrease symptoms, complications, or both. Retrospective data show decreased mortality, fewer hospital admissions, and fewer OCS bursts. All bronchodilators improve symptoms and exercise capacity. i. Treatment with an LA anticholinergic delays first exacerbation, reduces the overall number of COPD exacerbations and related hospitalizations, improves symptoms and health status (level of evidence A), and improves the effectiveness of pulmonary rehabilitation (level of evidence B). LA anticholinergics have no effect on the rate of decline of lung function. Initial studies with tiotropium showed elevated cardiovascular risk, but newer strong evidence shows no increase in risk. Anticholinergics may not significantly improve FEV 1 .
ii. LABAs improve health status, quality of life, and FEV 1 and decrease COPD exacerbation rate (level of evidence A). LABAs have no effect on mortality and rate of decline of lung function. Salmeterol reduces hospitalization rate (level of evidence B 7. Other pharmacologic treatments a. Phosphodiesterase-4 inhibitor: Roflumilast (Daliresp) i. Indication: As a daily treatment to reduce the risk of COPD exacerbations in patients with severe COPD (FEV 1 less than 50% of predicted) associated with chronic bronchitis and a history of frequent exacerbations. In these patients, studies show a reduction in exacerbations and a reduction in the composite end point of moderate exacerbations treated with oral or systemic corticosteroids or severe exacerbations requiring hospitalization or causing death (level of evidence B). These effects also occur when roflumilast is added to LA bronchodilators (level of evidence B). No trials have assessed the effects of roflumilast on COPD exacerbations when added to an ICS-LA bronchodilator combination. No comparison of adding roflumilast versus ICS to LA bronchodilators is available (currently being studied). ii. Mechanism: Reduces inflammation through inhibition of the breakdown of intracellular cyclic adenosine monophosphate; no direct bronchodilator activity. iii. Dose: 500 mcg orally once daily iv. Contraindications: Moderate to severe liver impairment; use in nursing mothers v. Precautions: Weight loss (monitor); psychiatric events including suicidality (monitor; weigh risk-benefit ratio in patients with preexisting psychiatric illness). Twenty percent of patients studied had weight loss of 5%-10% of body weight compared with 7% with placebo; average weight loss was 2 kg. vi. Adverse reactions: Diarrhea, weight loss or decreased appetite, nausea, headache, back pain, influenza, insomnia, and dizziness vii. Drug interactions: Use with strong cytochrome P450 (CYP) enzyme inducers is not recommended (e.g., rifampin, phenobarbital, carbamazepine, phenytoin); use with CYP3A4 inhibitors or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine) increases roflumilast exposure and adverse effects (risk-benefit ratio must be weighed). (Rutten et al. 2010 ). ii. More than half of the patients studied had cardiovascular risk factors or coronary artery disease. Mostly cardioselective β-blockers were used. iii. It is too early to recommend β-blockers for the treatment of COPD, but β-blockers should not be withheld in patients with COPD who also have heart disease, chronic heart failure, or other cardiovascular conditions in which β-blockers are beneficial (Salpeter 2002 (Salpeter , update 2005 , reviewed 2008) iv. Mechanism for benefit in COPD is unknown, but β-blockers can upregulate β 2 -receptors in the lungs, which may improve the effectiveness of inhaled β-agonists.
F. Management of Acute Exacerbations of Chronic COPD 1. A COPD exacerbation is an acute worsening of a patient's baseline respiratory symptoms (e.g., dyspnea, cough, and/or an increase in quantity or purulence of sputum) that is worse than normal day-to-day variation and results in a change in medication. Diagnosis is based purely on clinical presentation. 2. Common precipitating factors include infection of tracheobronchial tree and viral upper respiratory tract infections (most common) and air pollution. However, the cause of one-third of exacerbations cannot be determined. 3. Spirometry is not accurate during an exacerbation and is not recommended. 4. Pulse oximetry can be used to determine the need for supplemental oxygen, which should be given in severe exacerbations. In exacerbations requiring hospitalization, an arterial blood gas measurement should be performed. 
Patient Case
9.
A 64-year-old woman with COPD in GOLD patient group A presents for a clinic visit. In the past few days, she has had a worsening in shortness of breath and a productive cough with more "cloudy" and more copious sputum than usual. Pulse oximetry is 95% on room air. She has a nebulizer at home. In addition to regular use of albuterol plus ipratropium by nebulizer every 1-4 hours, which is the best course of action?
A a. Inadequate response defined as either less than 20% improvement in pain score in 24 hours or less than 50% improvement in 24 hours or more after starting drug therapy for acute attack. b. If inadequate response, switch to a different monotherapy (level of evidence C) or add a second agent (level of evidence C). c. Biologic agents that inhibit interleukin-1 (anakinra and canakinumab) are considered investigational for the treatment of acute gout but can be considered when gout flares are frequent and resistant to all other therapies. 5. Educate patients and provide a prescription so that patients can initiate treatment for acute gouty attacks on their own. ACR = American College of Rheumatology; CKD = chronic kidney disease; CrCl = creatinine clearance; CYP = cytochrome P450; ER = extended release; FDA = U.S. Food and Drug Administration; IM = intramuscular(ly); NSAID = nonsteroidal anti-inflammatory drug; OCS = oral corticosteroid; Pgp = P-glycoprotein; PUD = peptic ulcer disease; ULT = urate-lowering therapy; XOI = xanthine oxidase inhibitor.
Patient Cases
10.
A 60-year-old man presents with his third gouty attack in the past year. His last attack was 10 days ago, for which he took colchicine with good response. His pain is in his left knee and in the third and fourth proximal interphalangeal joints on his left hand. The pain started about 10 hours ago. He rates his pain as 6/10. He has COPD and dyslipidemia, his renal function is normal, and his weight is 80 kg. His uric acid level from 1 month ago is 10 mg/day. He has no tophi. His only medications are inhaled tiotropium, albuterol, and simvastatin. Which is most appropriate for treatment of this acute gouty attack?
A. Naproxen 750 mg, then 250 mg every 8 hours.
B. Colchicine 1.2 mg, then 0.6 mg in 1 hour, then 0.6 mg every 12 hours.
C. Intra-articular triamcinolone injection of all affected joints.
D. Prednisone 40 mg daily plus naproxen 750 mg, then 250 mg every 8 hours.
11. Which is most appropriate regarding ULT in this patient?
A. Probenecid should be started, but treatment should be delayed until after the acute attack is resolved.
B. Probenecid should be started and can be initiated during the acute attack.
C. Allopurinol should be started, but treatment should be delayed after the acute attack has resolved.
D. Allopurinol should be started and can be initiated during the acute attack.
12. Which regimen for anti-inflammatory prophylaxis with ULT therapy is most appropriate in this patient, once the acute attack has resolved?
A. Colchicine 0.6 mg once daily.
B. Prednisone 10 mg daily.
C. Colchicine 0.6 mg once daily plus naproxen 250 mg twice daily.
D. Pegloticase 8 mg intravenously every 2 weeks.
What is the initial goal uric acid level and duration of anti-inflammatory prophylaxis in this patient?
A. Goal <6 mg/dL; continue for a total of 6 months.
B. Goal <6 mg/dL; continue for 3 months after achieving goal serum urate for at least 6 months total.
C. Goal <5 mg/dL; continue for a total of 6 months.
D. Goal <5 mg/dL; continue for 3 months after achieving goal serum urate for at least 6 months total. Haemophilus influenzae type b (Hib) *,12 These schedules indicate the recommended age groups and medical indications for which administration of currently licensed vaccines is commonly recommended for adults ages 19 years and older, as of February 1, 2015. For all vaccines being recommended on the Adult Immunization Schedule: a vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Licensed combination vaccines may be used whenever any components of the combination are indicated and when the vaccine's other components are not contraindicated. For detailed recommendations on all vaccines, including those used primarily for travelers or that are issued during the year, consult the manufacturers' package inserts and the complete statements from the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/hcp/acip-recs/index.html). Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services. Hepatitis A *,10
IV. ADULT IMMUNIZATIONS
Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP
Hepatitis B *,11
Haemophilus influenzae type b (Hib) Haemophilus influenzae type b (Hib) *,12 These schedules indicate the recommended age groups and medical indications for which administration of currently licensed vaccines is commonly recommended for adults ages 19 years and older, as of February 1, 2015. For all vaccines being recommended on the Adult Immunization Schedule: a vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Licensed combination vaccines may be used whenever any components of the combination are indicated and when the vaccine's other components are not contraindicated. For detailed recommendations on all vaccines, including those used primarily for travelers or that are issued during the year, consult the manufacturers' package inserts and the complete statements from the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/hcp/acip-recs/index.html). Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services. The above recommendations must be read together with the footnotes on the following pages of this schedule. 
Influenza vaccination
• Annual vaccination against influenza is recommended for all persons aged 6 months or older.
• Persons aged 6 months or older, including pregnant women and persons with hives-only allergy to eggs can receive the inactivated influenza vaccine (IIV 
Tetanus, diphtheria, and acellular pertussis (Td/Tdap) vaccination
• Administer 1 dose of Tdap vaccine to pregnant women during each pregnancy (preferably during 27 to 36 weeks' gestation) regardless of interval since prior Td or Tdap vaccination.
• Persons aged 11 years or older who have not received Tdap vaccine or for whom vaccine status is unknown should receive a dose of Tdap followed by tetanus and diphtheria toxoids (Td) booster doses every 10 years thereafter. Tdap can be administered regardless of interval since the most recent tetanus or diphtheria-toxoid containing vaccine.
• Adults with an unknown or incomplete history of completing a 3-dose primary vaccination series with Td-containing vaccines should begin or complete a primary vaccination series including a Tdap dose.
• For unvaccinated adults, administer the first 2 doses at least 4 weeks apart and the third dose 6 to 12 months after the second. • For incompletely vaccinated (i.e., less than 3 doses) adults, administer remaining doses.
• Refer to the ACIP statement for recommendations for administering Td/Tdap as prophylaxis in wound management (see footnote 1).
Varicella vaccination
• All adults without evidence of immunity to varicella (as defined below) should receive 2 doses of single-antigen varicella vaccine or a second dose if they have received only 1 dose. • Vaccination should be emphasized for those who have close contact with persons at high risk for severe disease (e.g., health care personnel and family contacts of persons with immunocompromising conditions) or are at high risk for exposure or transmission (e.g., teachers; child care employees; residents and staff members of institutional settings, including correctional institutions; college students; military personnel; adolescents and adults living in households with children; nonpregnant women of childbearing age; and international travelers).
• Pregnant women should be assessed for evidence of varicella immunity. Women who do not have evidence of immunity should receive the first dose of varicella vaccine upon completion or termination of pregnancy and before discharge from the health care facility. The second dose should be administered 4 to 8 weeks after the first dose.
• Evidence of immunity to varicella in adults includes any of the following: -documentation of 2 doses of varicella vaccine at least 4 weeks apart; -U.S.-born before 1980, except health care personnel and pregnant women; -history of varicella based on diagnosis or verification of varicella disease by a health care provider; -history of herpes zoster based on diagnosis or verification of herpes zoster disease by a health care provider; or -laboratory evidence of immunity or laboratory confirmation of disease.
Human papillomavirus (HPV) vaccination
• Two vaccines are licensed for use in females, bivalent HPV vaccine (HPV2) and quadrivalent HPV vaccine (HPV4), and one HPV vaccine for use in males (HPV4).
• For females, either HPV4 or HPV2 is recommended in a 3-dose series for routine vaccination at age 11 or 12 years and for those aged 13 through 26 years, if not previously vaccinated.
• For males, HPV4 is recommended in a 3-dose series for routine vaccination at age 11 or 12 years and for those aged 13 through 21 years, if not previously vaccinated. Males aged 22 through 26 years may be vaccinated. • HPV4 is recommended for men who have sex with men through age 26 years for those who did not get any or all doses when they were younger. • Vaccination is recommended for immunocompromised persons (including those with HIV infection) through age 26 years for those who did not get any or all doses when they were younger. • A complete series for either HPV4 or HPV2 consists of 3 doses. The second dose should be administered 4 to 8 weeks (minimum interval of 4 weeks) after the first dose; the third dose should be administered 24 weeks after the first dose and 16 weeks after the second dose (minimum interval of at least 12 weeks).
• HPV vaccines are not recommended for use in pregnant women. However, pregnancy testing is not needed before vaccination. If a woman is found to be pregnant after initiating the vaccination series, no intervention is needed; the remainder of the 3-dose series should be delayed until completion or termination of pregnancy.
Zoster vaccination
• A single dose of zoster vaccine is recommended for adults aged 60 years or older regardless of whether they report a prior episode of herpes zoster. Although the vaccine is licensed by the U.S. Food and Drug Administration for use among and can be administered to persons aged 50 years or older, ACIP recommends that vaccination begin at age 60 years.
• Persons aged 60 years or older with chronic medical conditions may be vaccinated unless their condition constitutes a contraindication, such as pregnancy or severe immunodeficiency.
Measles, mumps, rubella (MMR) vaccination
• Adults born before 1957 are generally considered immune to measles and mumps. All adults born in 1957 or later should have documentation of 1 or more doses of MMR vaccine unless they have a medical contraindication to the vaccine or laboratory evidence of immunity to each of the three diseases. Documentation of provider-diagnosed disease is not considered acceptable evidence of immunity for measles, mumps, or rubella.
Measles component:
• A routine second dose of MMR vaccine, administered a minimum of 28 days after the first dose, is recommended for adults who: -are students in postsecondary educational institutions, -work in a health care facility, or -plan to travel internationally.
• Persons who received inactivated (killed) measles vaccine or measles vaccine of unknown type during 1963-1967 should be revaccinated with 2 doses of MMR vaccine.
Mumps component:
• A routine second dose of MMR vaccine, administered a minimum of 28 days after the first dose, is recommended for adults who: -are students in a postsecondary educational institution, -work in a health care facility, or -plan to travel internationally.
• Persons vaccinated before 1979 with either killed mumps vaccine or mumps vaccine of unknown type who are at high risk for mumps infection (e.g., persons who are working in a health care facility) should be considered for revaccination with 2 doses of MMR vaccine.
Rubella component:
• For women of childbearing age, regardless of birth year, rubella immunity should be determined. If there is no evidence of immunity, women who are not pregnant should be vaccinated. Pregnant women who do not have evidence of immunity should receive MMR vaccine upon completion or termination of pregnancy and before discharge from the health care facility.
Health care personnel born before 1957:
• For unvaccinated health care personnel born before 1957 who lack laboratory evidence of measles, mumps, and/or rubella immunity or laboratory confirmation of disease, health care facilities should consider vaccinating personnel with 2 doses of MMR vaccine at the appropriate interval for measles and mumps or 1 dose of MMR vaccine for rubella.
Pneumococcal (13-valent pneumococcal conjugate vaccine [PCV13] and 23-valent pneumococcal polysaccharide vaccine [PPSV23]) vaccination
• General information -When indicated, only a single dose of PCV13 is recommended for adults.
-No additional dose of PPSV23 is indicated for adults vaccinated with PPSV23 at or after age 65 years. -When both PCV13 and PPSV23 are indicated, PCV13 should be administered first; PCV13 and PPSV23 should not be administered during the same visit. -When indicated, PCV13 and PPSV23 should be administered to adults whose pneumococcal vaccination history is incomplete or unknown.
• Adults aged 65 years or older who -Have not received PCV13 or PPSV23: Administer PCV13 followed by PPSV23 in 6 to 12 months. -Have not received PCV13 but have received a dose of PPSV23 at age 65 years or older: Administer PCV13 at least 1 year after the dose of PPSV23 received at age 65 years or older. .) The first dose of the 2-dose hepatitis A vaccine series should be administered as soon as adoption is planned, ideally 2 or more weeks before the arrival of the adoptee.
Footnotes-Recommended Immunization
• Single-antigen vaccine formulations should be administered in a 2-dose schedule at either 0 and 6 to 12 months (Havrix), or 0 and 6 to 18 months (Vaqta). If the combined hepatitis A and hepatitis B vaccine (Twinrix) is used, administer 3 doses at 0, 1, and 6 months; alternatively, a 4-dose schedule may be used, administered on days 0, 7, and 21 to 30 followed by a booster dose at month 12.
Hepatitis B vaccination
• Vaccinate persons with any of the following indications and any person seeking protection from hepatitis B virus (HBV) infection: -sexually active persons who are not in a long-term, mutually monogamous relationship (e.g., persons with more than 1 sex partner during the previous 6 months); persons seeking evaluation or treatment for a sexually transmitted disease (STD); current or recent injection drug users; and men who have sex with men; -health care personnel and public safety workers who are potentially exposed to blood or other infectious body fluids; -persons with diabetes who are younger than age 60 years as soon as feasible after diagnosis; persons with diabetes who are age 60 years or older at the discretion of the treating clinician based on the likelihood of acquiring HBV infection, including the risk posed by an increased need for assisted blood glucose monitoring in long-term care facilities, the likelihood of experiencing chronic sequelae if infected with HBV, and the likelihood of immune response to vaccination; -persons with end-stage renal disease, including patients receiving hemodialysis, persons with HIV infection, and persons with chronic liver disease; -household contacts and sex partners of hepatitis B surface antigenpositive persons, clients and staff members of institutions for persons with developmental disabilities, and international travelers to countries with high or intermediate prevalence of chronic HBV infection; and -all adults in the following settings: STD treatment facilities, HIV testing and treatment facilities, facilities providing drug abuse treatment and prevention services, health care settings targeting services to injection drug users or men who have sex with men, correctional facilities, end-stage renal disease programs and facilities for chronic hemodialysis patients, and institutions and nonresidential day care facilities for persons with developmental disabilities.
• Administer missing doses to complete a 3-dose series of hepatitis B vaccine to those persons not vaccinated or not completely vaccinated. The second dose should be administered 1 month after the first dose; the third dose should be given at least 2 months after the second dose (and at least 4 months after the first dose). If the combined hepatitis A and hepatitis B vaccine (Twinrix) is used, give 3 doses at 0, 1, and 6 months; alternatively, a 4-dose Twinrix schedule, administered on days 0, 7, and 21 to 30 followed by a booster dose at month 12 may be used.
• Adult patients receiving hemodialysis or with other immunocompromising conditions should receive 1 dose of 40 mcg/mL (Recombivax HB) administered on a 3-dose schedule at 0, 1, and 6 months or 2 doses of 20 mcg/mL (Engerix-B) administered simultaneously on a 4-dose schedule at 0, 1, 2, and 6 months.
Haemophilus influenzae type b (Hib) vaccination
• One dose of Hib vaccine should be administered to persons who have anatomical or functional asplenia or sickle cell disease or are undergoing elective splenectomy if they have not previously received Hib vaccine. Hib vaccination 14 or more days before splenectomy is suggested.
• Recipients of a hematopoietic stem cell transplant (HSCT) should be vaccinated with a 3-dose regimen 6 to 12 months after a successful transplant, regardless of vaccination history; at least 4 weeks should separate doses. • Hib vaccine is not recommended for adults with HIV infection since their risk for Hib infection is low.
Immunocompromising conditions
• Inactivated vaccines generally are acceptable (e.g., pneumococcal, meningococcal, and inactivated influenza vaccine) and live vaccines generally are avoided in persons with immune deficiencies or immunocompromising conditions. Information on specific conditions is available at www.cdc.gov/vaccines/hcp/acip-recs/index.html. 3 • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component • Known severe immunodeficiency (e.g., from hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, or long-term immunosuppressive therapy, 4 or patients with HIV infection who are severely immunocompromised) • Pregnancy
Footnotes-Recommended Immunization
• Moderate or severe acute illness with or without fever • Recent (within 11 months) receipt of antibody-containing blood product (specific interval depends on product) 5 • History of thrombocytopenia or thrombocytopenic purpura • Need for tuberculin skin testing 6 Pneumococcal conjugate (PCV13) • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component, including to any vaccine containing diphtheria toxoid
• Moderate or severe acute illness with or without fever Pneumococcal polysaccharide (PPSV23)
• Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component
• Moderate or severe acute illness with or without fever i. If IIV3, IIV4, or ccIIV3 is used, the health care provider administering the vaccine should be familiar with manifestations of egg allergy. ii. The vaccine recipient should be observed for at least 30 minutes after each vaccine dose. iii. If RIV3 is used, no special precautions are necessary. b. If a patient has experienced a severe reaction to eggs, such as angioedema, respiratory distress, lightheadedness, or recurrent emesis, or required epinephrine or emergency treatment, he or she may receive RIV3 (if age 18-49 years). i. If RIV3 is not available or the recipient is outside the age range, any of the IIVs can be used but should be administered by a physician with experience in recognition and management of severe allergic conditions. ii. The vaccine recipient should be observed for at least 30 minutes after each vaccine dose. c. Some people who report egg allergies may not actually be allergic to eggs. Those who are able to eat lightly cooked egg (e.g., scrambled egg) without a reaction are not likely to be allergic and can receive any influenza vaccine.
C. Current Issues with Herpes Zoster Vaccine (HZV): The HZV package insert states not to give HZV and PPSV concurrently but to separate them by at least 4 weeks because of decreased immunologic response to HZV. Their conclusion is based on a Merck-sponsored, unpublished study. The ACIP states that the clinical relevance of this recommendation is unknown, and a subsequent study showed no compromise in HZV efficacy. The Advisory Committee on Immunization Practices/Centers for Disease Control and Prevention (ACIP/CDC), which reviewed the data, continues to recommend that HZV and PPSV be administered at the same visit if the person is eligible for both vaccines.
Answer: D
According to the latest GOLD guidelines, OCSs are indicated in most exacerbations. The recommended dose is oral prednisone 40 mg daily for 5 days. Antibiotic treatment is also indicated because the patient has all three cardinal symptoms of airway infection: increased sputum purulence, increased sputum volume, and increased dyspnea. Trimethoprim/sulfamethoxazole is one of the recommended antibiotics.
Answer: A
NSAIDs (in anti-inflammatory or acute pain doses), colchicine, or corticosteroids are all appropriate for first-line therapy for acute gout. However, colchicine would not be recommended for this patient because he took acute colchicine doses in the past 2 weeks. Intra-articular corticosteroids are recommended only if only one or two large joints are affected. This patient is having an acute gouty attack of moderate severity. Combination therapy is recommended for initial therapy only if the patient has a severe attack. Oral prednisone alone would also be appropriate; however, this was not a choice.
Answer: D
Urate-lowering therapy is indicated in this patient because he has had two or more attacks in the past year. Allopurinol and febuxostat (XOIs) are first-line ULTs; probenecid is an alternative first-line ULT only if XOIs are contraindicated or not tolerated. Urate-lowering therapy can be initiated during an acute gouty attack, according to the American College of Rheumatology guidelines, as long as anti-inflammatory prophylaxis is instituted.
Answer: A
Oral corticosteroids are associated with significant risks in long-term therapy; they should not be used for anti-inflammatory prophylaxis unless both colchicine and NSAIDs are contraindicated, not tolerated, or ineffective. Combination therapy is not recommended for anti-inflammatory prophylaxis. Pegloticase is ULT, not anti-inflammatory prophylaxis.
Answer: B
If no tophi are present, the initial goal serum urate is <6 mg/dL; if gouty signs and symptoms are still present, then a secondary goal urate is <5 mg/dL. Antiinflammatory prophylaxis if no tophi are present should continue for 3 months after goal serum urate is achieved, as long as the total duration is at least 6 months.
Answer: D
The CDC recommends that the influenza vaccine be given every year in every person 6 months and older.
People 65 years and older should have a one-time pneumococcal (PPSV23) revaccination if they were vaccinated 5 or more years previously and were younger than 65 years at the time of primary vaccination. Zoster vaccination is recommended in all adults 60 years and older, regardless of previous zoster infection. The Tdap vaccine is recommended in all people, now including those 65 years and older.
First-year college students up to age 21 who live in dormitories, if not previously vaccinated on or after age 16, should receive the meningococcal vaccine (MenACWY; Menactra, Menevo). The PPSV23 is recommended for smokers 19-64 years of age, and this patient is a smoker. The Td vaccine should be given every 10 years. In adults younger than 65, a one-time dose of Tdap should be given, regardless of the time interval since the most recent tetanus vaccination. The HPV vaccine is for girls and women 11-26 years of age. Ideally, it should be given before the start of sexual activity, but it should still be administered to sexually active girls and women.
Answer: B
In people with an egg allergy who have only hives, either IIV3, IIV4, ccIIV3, or RIV3 can be used; LAIV should be avoided. The vaccine should be administered by a health professional with knowledge of the manifestations of egg allergy, and the patient should be observed for 30 minutes after administration.
